SGP · SpyGlass Pharma, Inc.
$26.51
+0.28 (+1.07%)
At close · Aug 21
Market Cap
$886.71M
Shares
33.45M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Habib Dable | Class I director | Appointed | 2026-02-09 |
Key facts
CIK
1778922
CUSIP
85220G109
13F (30d)
50 filings
50 filers
Visit website
Investor relations